Omnicell (OMCL) Q3 2026 earnings review
Omnicell raises its profit plan, but its hardware sales shrink
Omnicell, which makes automated medicine cabinets and pharmacy software for hospitals, expanded its profit margins while its hardware sales shrank. Third-quarter revenue slipped 1% from a year ago to $308 million, but profit per share excluding one-offs rose 14% because service delivery costs and overhead fell. Chief executive Randall A. Lipps raised the full-year profit plan again, yet by our math the fourth-quarter outlook points to revenue falling 5%.
| Revenue | $307.9M -0.9% from a year ago |
|---|---|
| EBITDA, excluding one-offs | $44.9M +9.2% from a year ago |
| Full-year revenue outlook | Cut $7M middle of the range: $1.228B (+3.6%) |
| Full-year recurring revenue outlook | Cut $5M middle of the range: $665M (+4.6%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because forward demand indicators weakened for a second straight quarter despite Lipps citing strong momentum for the new Titan XT cabinet and OmniSphere cloud platform. Omnicell cut its full-year hardware revenue and recurring revenue midpoints again, and left its full-year order target $135 million wide with only two months left in the year. The good news: third-quarter EBITDA excluding one-offs beat the middle of its outlook by 30% without last quarter's tariff refund, proving the service margin gains are real.
The question now is whether hospitals are merely taking longer to approve large platform upgrades or holding back on orders altogether. If the issue is approval timing, orders will rebound as the new cabinet ships; if demand is weaker, next year's sales will start from a smaller backlog. Full-year product bookings and the 2027 outlook in the fourth-quarter report will settle it.
🐂 Bull Case
Service Margins and Cost Cuts Drove a 30% Profit Beat
Omnicell makes automated medicine cabinets and pharmacy software for hospitals. Last quarter's profit included a $15 million tariff refund, which raised questions about underlying earnings power. In the third quarter, the company attributed its profit beat to "favorable product and service margins and disciplined cost management" without any refund help.
- EBITDA excluding one-offs: $44.9 million, up 9.2% from a year ago and 30.2% above the middle of its outlook
- Service gross margin excluding one-offs: 47.6%, up 5.5 percentage points from a year ago
- Cost of service revenues: 23.3% of total sales, down 2.2 percentage points from a year ago by our math
- Research and overhead costs: 39.9% of sales, down 0.7 percentage points from a year ago
This matters because service margin expansion more than offset a 2.0-point drop in hardware gross margin. Because third-quarter profit cleared the outlook by $10.4 million at the middle of the range, Omnicell raised its full-year EBITDA plan by $10 million even while cutting its sales forecast.
What to watch: fourth-quarter EBITDA excluding one-offs against the $30–36 million outlook. A fourth consecutive double-digit beat would show that service margin gains can protect earnings even while hardware shipments fall.
Customer Leasing Expanded 19% in One Quarter
Omnicell offers sales-type leases, which let hospitals finance new medication cabinets on multi-year contracts instead of paying cash up front. The pharmacy automation group uses this financing option to help health systems manage tight capital budgets and switch from rival equipment.
In the third quarter, long-term investment in sales-type leases on the balance sheet rose to $67.3 million, up from $56.5 million in June and $60.7 million at year-end. By our math, that is a 19.1% jump in a single quarter after the balance shrank in the first half of the year, and cash flow statements show $8.2 million invested in leases over the first nine months.
What to watch: the full-year leasing balance and bookings share in the annual report. Continued growth in customer financing would show that leasing is helping hospitals commit to orders during the hardware transition.
🐻 Bear Case
Product Revenue Outlook Cut Again as Q4 Drop Deepens
Omnicell's product revenue comes from installing automated dispensing cabinets and pharmacy robotics, which relies on the order backlog built in prior quarters. Management said third-quarter sales came in "above the high end of our previously provided guidance range", as total revenue of $307.9 million beat the $301–307 million plan.
Despite that $3.9 million beat against the middle of the third-quarter range, the company cut its full-year revenue midpoint by $7.0 million, to $1.228 billion. The entire reduction landed on hardware: Omnicell lowered its full-year product revenue midpoint by $9.5 million, to $685.5 million, marking a second consecutive cut. By our math, the new fourth-quarter outlook of $295–301 million sits 3.6% below what the prior full-year plan implied.
This matters because the fourth-quarter outlook points to total revenue falling 5.1% from a year ago and product revenue dropping 9.7% at the middle of the range. Even if the healthcare technology maker beats its fourth-quarter revenue plan by its usual 1.1% average, fourth-quarter sales would still decline about 4% from a year ago by our math.
What to watch: the year-end product backlog disclosed in the fourth-quarter report. A drop from last year's $640 million backlog would mean hardware revenue keeps shrinking into 2027.
Wide Bookings Range and Trimmed Recurring Revenue
"At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline," chief executive Randall A. Lipps said. That platform pairs Titan XT, its new medication dispensing cabinet, with OmniSphere, its cloud software "intended to improve productivity, efficiency, and workflow reliability". Supporters view these multi-product upgrades as the driver of an eight-year equipment replacement cycle.
Yet the forward numbers weakened again. Omnicell trimmed the top end of its year-end annual recurring revenue (ARR, the yearly value of consumables, technical services, and cloud software) outlook by $10 million, to $660–670 million, "with the low end unchanged, reflecting our increased visibility into the business as we approach year end". It also left its full-year product bookings target at $425–560 million, "which continues to reflect our current assessment of the range of potential outcomes for full year 2026".
- Year-end ARR outlook midpoint: $665 million, down from $670 million last quarter and $690 million at the start of the year
- Implied 2026 net new ARR: $29.4 million at the middle of the range, down 47% from the $55.5 million added in 2025 by our math
- Product bookings range: $135 million wide with one quarter left, with the $492.5 million midpoint down 7.9% from 2025
What to watch: full-year 2026 product bookings in the fourth-quarter release. A figure near the $425 million floor would show that long hospital approval cycles are delaying orders rather than converting the pipeline.
Risks this quarter didn't answer
Several standing concerns around software pricing, hardware component costs, hospital budgets, and smaller product lines received no update in the third-quarter earnings release.
- OmniSphere software pricing: no monetization model or revenue date was disclosed; management previously promised details alongside the 2027 outlook next quarter.
- Product gross margin and memory-chip costs: hardware gross margin excluding one-offs fell 2.0 percentage points from a year ago to 43.8%, and cost of product rose 0.8 points of sales; the quarterly filing will show how much came from memory-chip inflation.
- Hospital budgets and tariffs: the release gave no update on how state Medicaid cuts or Section 301 tariffs are affecting customer order timing; fourth-quarter bookings will test hospital capital spending.
- IV compounding robotics and EnlivenHealth retail pharmacy software: neither product line was broken out in the release; the quarterly filing's management discussion will show if robotics sales kept falling.
👓 Other Themes
Beijing Office Exit Adds to Restructuring Charges
Omnicell recorded $652 thousand of severance and related costs in the third quarter for the "exit of our Beijing, China office as part of our operating model adjustments". That follows $1.9 million for product organization restructuring and $1.8 million for professional services adjustments in the second quarter, bringing total restructuring charges excluded from non-GAAP profit to $4.3 million over the first nine months of 2026.
💲 Other KPIs
Total deferred revenue — cash billed to customers for equipment and services not yet delivered — rose 7.4% from a year ago and $15.7 million from last quarter, by our math. That reversed last quarter's seasonal dip and widened the year-over-year lead from 5.9% in June, supporting near-term service revenue.
Free cash flow — operating cash flow minus property purchases and software development costs — climbed 42.6% from a year ago in the third quarter. Over the first nine months, free cash flow reached $114.4 million against $51.0 million a year earlier, helped by higher operating profit and lower software development spending.
Cash on the balance sheet rose from $292.2 million in June and $196.5 million at year-end, leaving $146.4 million of net cash above its $168.5 million of convertible debt by our math. The pharmacy technology group bought back no shares for a third consecutive quarter, while diluted share count rose 1.2% from a year ago.
🔮 Guidance
Cut against the prior implied range. The plan calls for fourth-quarter sales to fall 5.1% from a year ago and 3.2% from the third quarter at the middle of the range, by our math. That sits 3.6% below the $309 million middle implied by last quarter's full-year outlook. If its four-quarter average beat of 1.1% holds, fourth-quarter revenue would land near $301.4 million.
New. The fourth-quarter hardware plan points to a 9.7% drop from a year ago and a 6.1% decline from the third quarter at the middle of the range, by our math. The step-down reflects tougher comparisons against last year's fourth quarter and slower conversion of hardware orders ahead of the Titan XT cabinet rollout.
New. Management expects fourth-quarter service revenue to rise 1.0% from a year ago and 0.5% from the third quarter at the middle of the range, by our math. Growing deferred revenue and technical service contracts keep the service line steady while hardware shrinks.
New. The plan puts fourth-quarter EBITDA excluding one-offs down 10.3% from a year ago and down 26.6% from the third quarter at the $33 million middle, by our math, equal to an 11.1% margin. If the company's 25.8% average beat over the last four quarters holds, fourth-quarter EBITDA would reach $41.5 million.
New. The outlook calls for profit per share excluding one-offs to rise 12.5% from a year ago at the $0.45 middle of the range, but fall 22.4% from the third quarter's $0.58, by our math. Lower interest expense after last year's convertible note repayment helps the year-over-year comparison.
Cut. Omnicell kept the floor unchanged but trimmed $14 million off the top end, lowering the middle of the range by $7 million to $1.228 billion (+3.6% from 2025 by our math). After holding the midpoint at $1.235 billion for three straight quarters, the company absorbed a $3.9 million third-quarter beat and still lowered the year.
Cut. The full-year hardware midpoint fell by $9.5 million to $685.5 million (+3.0% from 2025 by our math). It is the second consecutive reduction from the initial $700 million midpoint set at the start of the year: $0M, -$5.0M, -$9.5M.
Raised. The middle of the full-year service outlook moved up $2.5 million to $542.5 million (+4.5% from 2025 by our math). It is the second raise this year: $0M, +$5.0M, +$2.5M.
Raised. The middle of the range rose $3.0 million to $272.5 million, following a $4.5 million increase last quarter. Technical services has carried all of the full-year service revenue upgrades this year.
Cut. The narrow new range trims the middle of the cloud and expert services outlook by $0.5 million to $270.0 million, where it has hovered all year.
Raised. The middle of the range rose $10.0 million to $190.0 million (+35.8% from 2025 by our math). It is the third consecutive raise across four quarters: +$8.0M, +$19.5M, +$10.0M. Because the third quarter beat its midpoint by $10.4 million, the full-year increase simply banks the third-quarter beat.
Raised. The middle of the range increased by $0.295 to $2.52 (+55.6% from 2025 by our math). It is the third raise this year: +$0.15, +$0.325, +$0.295.
Cut. Removing $10 million from the top end lowers the middle of the range by $5.0 million to $665.0 million (+4.6% from 2025 by our math). That follows a $20.0 million cut last quarter: $0M, -$20.0M, -$5.0M.
Unchanged. Management kept the $135 million-wide range after cutting the floor by $85 million last quarter. At the $492.5 million middle of the range, full-year bookings would fall 7.9% from 2025's $535 million, by our math.
❓ Key Questions
Why keep a $135 million bookings range in late October?
With only two months left in the fiscal year, the $425–560 million product bookings outlook spans 27% of its own midpoint. How much of that gap depends on a few large hospital deals closing before December 31?
What drove the second consecutive cut to recurring revenue?
Omnicell trimmed the top end of its year-end ARR outlook by $10 million after a $20 million cut in July, while holding SaaS and raising technical services. Did consumables demand weaken again in the third quarter?
Why did hardware gross margin drop 2 points in Q3?
Product gross margin excluding one-offs fell from 45.8% a year ago to 43.8%. How much of that 2.0-point drop came from the $6 million second-half memory-chip cost headwind versus lower hardware volume?
Will management still detail OmniSphere pricing next quarter?
Last quarter management promised to share go-to-market, monetization, and ramp expectations for the OmniSphere cloud platform alongside 2027 guidance. Is that disclosure still on track for the fourth-quarter report?
What is the plan for the $315 million cash balance?
Cash and equivalents have grown by $118 million this year to $314.9 million, while share buybacks remained at zero for a third straight quarter. How much cash is reserved for funding customer leases versus a new buyback program?